Authors: Schmidt, A.C.¹; Bramlage, P.²; Lichtenthal, A.³; Eckert, M.⁴; Scholze, J.¹

Source: Current Medical Research and Opinion, Volume 23, Number 8, August 2007 , pp. 1987-1995(9)

Publisher: Informa Healthcare

Abstract:

Objective: The risk of arterial hypertension and subsequent cardiovascular disease morbidity and mortality increases with low socio-economic status (SES). Even small differences in blood pressure, whether untreated or despite treatment, account for this substantial difference. Most of the increased risk in the low socio-economic group is due to traditional cardiovascular risk factors such as overweight and obesity, alcohol consumption and a sedentary life style. Intense treatment of arterial hypertension has been shown to overcome these prognostic inequalities. Therefore, drugs with high efficacy, optimal treatment adherence and a low potential for drug-related side effects are needed in order to reduce the cardiovascular risk burden of patients with a low SES. The angiotensin receptor blocker (ARB) olmesartan will be used to investigate the effectiveness of this drug in different socio-economic classes.

Research design and methods: The LEO (Long-term Effectiveness of Olmesartan in different Socioeconomic groups) study is a large observational long-term study which has been set up to test the effectiveness of olmesartan within this context. The study has a matched-pairs design (1403 patients in both the low and the high socio-economic classes).

Main outcome measures: The LEO study will test whether this regimen can reduce the SES-related difference in long-term blood pressure control and compliance in the low SES population.

Conclusions: The study may generate valuable information about the antihypertensive effectiveness of olmesartan alone or in combination with hydrochlorothiazide in different socio-economic classes. It will further test whether the drug helps to reduce the inherent inequalities in cardiovascular prognosis between different socio-economic groups.

Current status: The study commenced in July 2007. Results are anticipated in December 2008.

Keywords: COMPLIANCE; EFFECTIVENESS; HYPERTENSION; PERSISTENCE; SOCIO-ECONOMIC CLASS; STUDY DESIGN

Document Type: Research article

DOI: http://dx.doi.org/10.1185/030079907X226078

Affiliations: 1: Charité-Universitaetsmedizin, Department of Internal Medicine, Outpatient Clinic, Berlin, Germany 2: Institute for Clinical Pharmacology, Medical Faculty Carl-Gustav Carus, Technical University Dresden, Dresden, Germany 3: Berlin-Chemie AG, Medicine & Research, Cardiovascular Dept., Berlin, Germany 4: SIMW GmbH, Wegberg, Germany

Publication date: 2007-08-01

More about this publication?

• Information for Authors
• Subscribe to this Title
• Terms & Conditions
• General Information
• Journal Information
• ingentaconnect is not responsible for the content or availability of external websites

Related content

• In this: publication
• By this: publisher
• In this Subject: Medicine (General)
• By this author: Schmidt, A.C. ;  Bramlage, P. ;  Lichtenthal, A. ;  Eckert, M. ;  Scholze, J.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers